A citation-based method for searching scientific literature

Carol Aghajanian, Stephanie V Blank, Barbara A Goff, Patricia L Judson, Michael G Teneriello, Amreen Husain, Mika A Sovak, Jing Yi, Lawrence R Nycum. J Clin Oncol 2012
Times Cited: 781

U Wagner, C Marth, R Largillier, J Kaern, C Brown, M Heywood, T Bonaventura, I Vergote, M C Piccirillo, R Fossati, V Gebski, E P Lauraine. Br J Cancer 2012
Times Cited: 98

List of shared articles

Times cited

Chemotherapeutic Regimens and Chemotherapy-Free Intervals Influence the Survival of Patients with Recurrent Advanced Epithelial Ovarian Carcinoma: A Retrospective Population-Based Study.
Hsin-Ying Huang, Chun-Ju Chiang, Yun-Yuan Chen, San-Lin You, Heng-Cheng Hsu, Chao-Hsiun Tang, Wen-Fang Cheng. Int J Environ Res Public Health 2021

Clinical benefit of systemic therapies for recurrent ovarian cancer-ESMO-MCBS scores.
K E Broekman, M van Kruchten, H van Tinteren, C Sessa, M Jalving, A K L Reyners. ESMO Open 2021

Cediranib in addition to chemotherapy for women with relapsed platinum-sensitive ovarian cancer (ICON6): overall survival results of a phase III randomised trial.
J A Ledermann, A C Embleton-Thirsk, T J Perren, G C Jayson, G J S Rustin, S B Kaye, H Hirte, A Oza, M Vaughan, M Friedlander,[...]. ESMO Open 2021

Real world outcomes in platinum sensitive relapsed ovarian, fallopian tube, or peritoneal cancer treated in routine clinical practice in the United Kingdom prior to poly-ADP ribose polymerase inhibitors.
Rosemary Lord, Jyoti Rauniyar, Tamsin Morris, Orlaith Condon, Rachel Jones, Rowan Miller, Marcia Hall, Fiona Lofts, Rosalind M Glasspool, Emma Hudson. Int J Gynecol Cancer 2020

Phase 1b study of anti-NaPi2b antibody-drug conjugate lifastuzumab vedotin (DNIB0600A) in patients with platinum-sensitive recurrent ovarian cancer.
Kathleen N Moore, Michael J Birrer, Jim Marsters, Yulei Wang, YounJeong Choi, Stephanie Royer-Joo, Vanessa Lemahieu, Katy Armstrong, Julie Cordova, Divya Samineni,[...]. Gynecol Oncol 2020